Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices 4935 

Dated: January 22, 2015. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2015–01685 Filed 1–28–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Miniature System for Manipulating 

Small Animals in High-Throughput 

Screening Small Molecules 

Description of Technology: The 

invention pertains to a miniaturized 

plating and feeding system based on a 

96-well microplate base and is intended 

to reduce manipulation of organisms as 

well as amounts of test drug/anesthetic, 

thereby mitigating waste. The kit 

comprises a feeder plate, transfer 

adaptor and receiver plate. The feeder 

plate is defined by, for example, a 

plastic 96-well plate with rounded 

wells. The rounded bottoms can 

dispense to or permit access to the test 

organism of liquid food or drug through 

about 7 holes of approximately 350 

microns in diameter. A top portion of 

the well provides test organisms (e.g., 

drosophila, daphnia) with sufficient 

space to enjoy normal life-cycles 

without confinement stress. The feeder 

plate includes means for interfacing 

with complementary components of the 

transfer and receiver plates through 

receiving holes and complementary 

dowels or pins. A transfer adapter 

allows the interconnection of the feeder 

plate to the receiver plate. The transfer 

plate can be configured to be square or 

rounded for the transfer of organisms 

from the feeder plate to the receiver 

plate. 

Potential Commercial Applications 

• Drug Development 

• Toxicity Studies 

• Drug Design 

Competitive Advantages 

• Small animals 

• High Throughput 

• Space efficiency 

• Resource economy 

Development Stage 

• Early stage 

• Prototype 

Inventors: Maria De Los Angeles Jaime 

and Brian Oliver (NIDDK). 

Intellectual Property: HHS Reference 

No. E–034–2015/0—US Provisional 

Application No. 62/080,181 filed 

November 14, 2015. 

Licensing Contact: Michael 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize 

High-Throughput Small Animal 

Manipulation for Drug Design. For 

collaboration opportunities, please 

contact Marguerite J. Miller at 

millermarg@niddk.nih.gov. 

LRKK2 Inhibitors: Novel Treatment for 

Intestinal Bowel Disorders 

Description of Technology: Use of 

Leucine Rich Repeat Kinase 2 (LRRK2) 

inhibitors for the treatment of Intestinal 

Bowel Disorders (IBD) is disclosed. IBD 

is a broad term that describes conditions 

with chronic or recurring immune 

response and inflammation of the 

gastrointestinal tract. Crohn’s disease 

and ulcerative colitis, two common 

forms of idiopathic IBD, are chronic, 

relapsing inflammatory disorders of the 

gastrointestinal tract. 

LRRK2 is a kinase encoded by a gene 

that contains a non-coding 

polymorphism (SNP). LRRK2 has been 

associated with and is a risk factor for 

inflammatory bowel disease. NIH 

inventors have shown that human cells 

expressing this SNP have increased 

levels of LRRK2 and, correspondingly, 

mice with increased levels of LRRK2 

exhibit more severe Dextran Sulfate 

colitis. In various studies of the role of 

LRRK2 in cell signaling, NIH inventors 

have shown that increased levels of 

LRRK2 lead to increased proinflammatory cytokine secretion. Also, 

an inhibitor of LRRK2 is shown to 

abrogate the pro-inflammatory activity 

of LRRK2 both in vitro and in vivo. 

Potential Commercial Applications: 

Treatment for or prevention of Intestinal 

Bowel Disorders. 

Competitive Advantages 

• A LRRK2 inhibitor would be a 

unique form of anti-inflammatory 

therapy that will complement or 

compete with an array of cytokines in 

primary treatment for lBD. 

• A LRRK2 inhibitor would provide a 

much needed alternate mode of therapy. 

Development Stage 

• Early-stage 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Warren Strober, Ivan J. 

Fuss, Tetsuya Takagawa, Atsushi Kitani 

(all of NIAID). 

Intellectual Property: HHS Reference 

No. E–070–2014/0—US Provisional 

Application No. 61/993,637 filed May 

15, 2014. 

Licensing Contact: Suryanarayana 

Vepa, Ph.D., J.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Dated: January 22, 2015. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2015–01610 Filed 1–28–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

mstockstill on DSK4VPTVN1PROD with NOTICES